Carnosine decreases IGFBP1 production in db/db mice through suppression of HIF-1

Journal of Endocrinology

Volumn 225, Issue 3, 2015, Pages 159-167

  Forsberg, Elisabete A ^a   Botusan, Ileana R ^a   Wang, Jing ^a   Peters, Verena ^c   Ansurudeen, Ishrath ^a   Brismar, Kerstin ^a,b   Catrina, Sergiu Bogdan ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Carnosine; HIF 1 ; IGFBP1; Liver

Indexed keywords

BIOLOGICAL MARKER; CARNOSINE; DRINKING WATER; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; LEPTIN; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 1; ANTIOXIDANT; HIF1A PROTEIN, HUMAN; HIF1A PROTEIN, MOUSE; IGFBP1 PROTEIN, HUMAN; IGFBPL-1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HEPG2 CELL LINE; HETEROZYGOSITY; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIVER; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REPORTER GENE; WESTERN BLOTTING; ANIMAL; BLOOD; CELL HYPOXIA; COMPLICATION; DIET SUPPLEMENTATION; DIET THERAPY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; GENETICS; HETEROZYGOTE; INSULIN RESISTANCE; METABOLISM; MUTANT MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SECRETION (PROCESS);

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARNOSINE; CELL HYPOXIA; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOWN-REGULATION; GENES, REPORTER; HEP G2 CELLS; HETEROZYGOTE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; LIVER; MALE; MICE, MUTANT STRAINS; OBESITY; RESPONSE ELEMENTS;

EID: 84932122269     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0571     Document Type: Article

References (50)

1. Ahluwalia TS, Lindholm E & Groop LC 2011 Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia 54 2295-2302. (doi:10.1007/s00125-011-2178-5)
2. Ansurudeen I, Sunkari VG, Grunler J, Peters V, Schmitt CP, Catrina SB, Brismar K & Forsberg EA 2012 Carnosine enhances diabetic wound healing in the db/db mouse model of type 2 diabetes. Amino Acids 43 127-134. (doi:10.1007/s00726-012-1269-z)
3. Bang P, Eriksson U, Sara V, Wivall IL & Hall K 1991 Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinologica 124 620-629.
4. Boldyrev AA, Aldini G & Derave W 2013 Physiology and pathophysiology of carnosine. Physiological Reviews 93 1803-1845. (doi:10.1152/physrev. 00039.2012)
5. Brismar K, Fernqvist-Forbes E, Wahren J & Hall K 1994 Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. Journal of Clinical Endocrinology and Metabolism 79 872-878. (doi:10.1210/jcem. 79.3.7521354)
6. Brown BE, Kim CH, Torpy FR, Bursill CA, McRobb LS, Heather AK, Davies MJ & van Reyk DM 2014 Supplementation with carnosine decreases plasma triglycerides and modulates atherosclerotic plaque composition in diabetic apo E(K/K) mice. Atherosclerosis 232 403-409. (doi:10.1016/j.atherosclerosis.2013.11.068)
7. Catrina SB 2014 Impaired hypoxia-inducible factor (HIF) regulation by hyperglycemia. Journal of Molecular Medicine 92 1025-1034. (doi:10.1007/s00109-014-1166-x)
8. Clauson PG, Brismar K, Hall K, Linnarsson R & Grill V 1998 Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scandinavian Journal of Clinical and Laboratory Investigation 58 353-360. (doi:10.1080/00365519850186544)
9. Crossey PA, Jones JS & Miell JP 2000 Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes 49 457-465. (doi:10.2337/diabetes.49.3.457)
10. Doublier S, Seurin D, Fouqueray B, Verpont MC, Callard P, Striker LJ, Striker GE, Binoux M & Baud L 2000 Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1. Kidney International 57 2299-2307. (doi:10.1046/j.1523-1755.2000.00090.x)
11. Ezzat VA, Duncan ER, Wheatcroft SB & Kearney MT 2008 The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes, Obesity & Metabolism 10 198-211. (doi:10.1111/j.1463-1326.2007.00709.x)
12. Freedman BI, Hicks PJ, Sale MM, Pierson ED, Langefeld CD, Rich SS, Xu J, McDonough C, Janssen B, Yard BA et al. 2007 A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrology, Dialysis, Transplantation 22 1131-1135. (doi:10.1093/ndt/gfl717)
13. Gallant S, Semyonova M & Yuneva M 2000 Carnosine as a potential antisenescence drug. Biochemistry 65 866-868.
14. Guiotto A, Calderan A, Ruzza P & Borin G 2005 Carnosine and carnosinerelated antioxidants: a review. Current Medicinal Chemistry 12 2293-2315. (doi:10.2174/0929867054864796)
15. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A et al. 2001 Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 44 333-339. (doi:10.1007/s001250051623)
16. Hilding A, Hall K, Skogsberg J, Ehrenborg E & Lewitt MS 2003 Troglitazone stimulates IGF-binding protein-1 by a PPARg-independent mechanism. Biochemical and Biophysical Research Communications 303 693-699. (doi:10.1016/S0006-291X(03)00403-0)
17. Hummel KP, Dickie MM & Coleman DL 1966 Diabetes, a new mutation in the mouse. Science 153 1127-1128. (doi:10.1126/science.153. 3740.1127)
18. Iovine B, Oliviero G, Garofalo M, Orefice M, Nocella F, Borbone N, Piccialli V, Centore R, Mazzone M, Piccialli G et al. 2014 The anti-proliferative effect of L-carnosine correlates with a decreased expression of hypoxia inducible factor 1α in human colon cancer cells. PLoS ONE 9 e96755. (doi:10.1371/journal.pone.0096755)
19. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, Rychlik I, Cerna M, Romzova M, de Heer E et al. 2005 Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 54 2320-2327. (doi:10.2337/diabetes.54.8.2320)
20. Ji YS, Park JW, Heo H, Park JS & Park SW 2014 The neuroprotective effect of carnosine (β-alanyl-L-histidine) on retinal ganglion cell following ischemia-reperfusion injury. Current Eye Research 39 634-641. (doi:10.3109/02713683.2013.855235)
21. Kaelin WG Jr & Ratcliffe PJ 2008 Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular Cell 30 393-402. (doi:10.1016/j.molcel.2008.04.009)
22. Kubomura D, Matahira Y, Nagai K & Niijima A 2010a Effect of anserine ingestion on hyperglycemia and the autonomic nerves in rats and humans. Nutritional Neuroscience 13 183-188. (doi:10.1179/147683010X12611460764363)
23. Kubomura D, Matahira Y, Nagai K & Niijima A 2010b Effect of anserine ingestion on the hyperglycemia and autonomic nerves in rats and humans. Nutritional Neuroscience 13 123-128. (doi:10.1179/147683010X12611460764048)
24. Kurashige M, Imamura M, Araki S, Suzuki D, Babazono T, Uzu T, Umezono T, Toyoda M, Kawai K, Imanishi M et al. 2013 The influence of a single nucleotide polymorphism within CNDP1 on susceptibility to diabetic nephropathy in Japanese women with type 2 diabetes. PLoS ONE 8 e54064. (doi:10.1371/journal.pone.0054064)
25. Lenz GR & Martell AE 1964 Metal complexes of carnosine. Biochemistry 3 750-753. (doi:10.1021/bi00894a002)
26. Lewitt MS, Denyer GS, Cooney GJ & Baxter RC 1991 Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 129 2254-2256. (doi:10.1210/endo-129-4-2254)
27. Lindgren BF, Odar-Cederlof I, Ericsson F & Brismar K 1996 Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients? Growth Regulation 6 137-143.
28. Menini S, Iacobini C, Ricci C, Fantauzzi CB & Pugliese G 2015 Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice. Diabetologia 58 845-853. (doi:10.1007/s00125-014-3467-6)
29. Mesotten D, Delhanty PJ, Vanderhoydonc F, Hardman KV, Weekers F, Baxter RC & Van Den Berghe G 2002 Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. Journal of Clinical Endocrinology and Metabolism 87 5516-5523. (doi:10.1210/jc. 2002-020664)
30. Munoz MT, Barrios V, Pozo J & Argente J 1996 Insulin-like growth factor I, its binding proteins 1 and 3, and growth hormone-binding protein in children and adolescents with insulin-dependent diabetes mellitus: clinical implications. Pediatric Research 39 992-998. (doi:10.1203/00006450-199606000-00011)
31. Murphy LJ 2000 Overexpression of insulin-like growth factor binding protein-1 in transgenic mice. Pediatric Nephrology 14 567-571. (doi:10.1007/s004670000347)
32. Nagai K, Niijima A, Yamano T, Otani H, Okumra N, Tsuruoka N, Nakai M & Kiso Y 2003 Possible role of L-carnosine in the regulation of blood glucose through controlling autonomic nerves. Experimental Biology and Medicine 228 1138-1145.
33. Peters V, Kebbewar M, Jansen EW, Jakobs C, Riedl E, Koeppel H, Frey D, Adelmann K, Klingbeil K, Mack M et al. 2010 Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity. Amino Acids 38 1607-1615. (doi:10.1007/s00726-009-0367-z)
34. Peters V, Schmitt CP, Zschocke J, Gross ML, Brismar K & Forsberg E 2012 Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice. Amino Acids 42 2411-2416. (doi:10.1007/s00726-011-1046-4)
35. Peters V, Riedl E, Braunagel M, Hoger S, Hauske S, Pfister F, Zschocke J, Lanthaler B, Benck U, Hammes HP et al. 2014 Carnosine treatment in combination with ACE inhibition in diabetic rats. Regulatory Peptides 194-195 36-40. (doi:10.1016/j.regpep.2014.09.005)
36. Pfister F, Riedl E, Wang Q, vomHagen F, Deinzer M, Harmsen MC, Molema G, Yard B, Feng Y & Hammes HP 2011 Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. Cellular Physiology and Biochemistry 28 125-136. (doi:10.1159/000331721)
37. Powell DR, Allander SV, Scheimann AO, Wasserman RM, Durham SK & Suwanichkul A 1995 Multiple proteins bind the insulin response element in the human IGFBP-1 promoter. Progress in Growth Factor Research 6 93-101. (doi:10.1016/0955-2235(95)00034-8)
38. Rajaram S, Baylink DJ & Mohan S 1997 Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews 18 801-831. (doi:10.1210/edrv.18.6.0321)
39. Riedl E, Pfister F, Braunagel M, Brinkkotter P, Sternik P, Deinzer M, Bakker SJ, Henning RH, van den Born J, Kramer BK et al. 2011 Carnosine prevents apoptosis of glomerular cells and podocyte loss in STZ diabetic rats. Cellular Physiology and Biochemistry 28 279-288. (doi:10.1159/000331740)
40. Sauerhofer S, Yuan G, Braun GS, Deinzer M, Neumaier M, Gretz N, Floege J, Kriz W, van der Woude F & Moeller MJ 2007 L-carnosine, a substrate of carnosinase-1, influences glucose metabolism. Diabetes 56 2425-2432. (doi:10.2337/db07-0177)
41. Schrijvers BF, De Vriese AS & Flyvbjerg A 2004 From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocrine Reviews 25 971-1010. (doi:10.1210/er.2003-0018)
42. Semenza GL 2011 Oxygen sensing, homeostasis, and disease. New England Journal of Medicine 365 537-547. (doi:10.1056/NEJMra1011165)
43. Stephens RH, McElduff P, Heald AH, New JP, Worthington J, Ollier WE & Gibson JM 2005 Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes. Diabetes 54 3547-3553. (doi:10.2337/diabetes.54.12.3547)
44. Tazuke SI, Mazure NM, Sugawara J, Carland G, Faessen GH, Suen LF, Irwin JC, Powell DR, Giaccia AJ & Giudice LC 1998 Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. PNAS 95 10188-10193. (doi:10.1073/pnas.95.17.10188)
45. Van Buul-Offers SC, Van Kleffens M, Koster JG, Lindenbergh-Kortleve DJ, Gresnigt MG, Drop SL, Hoogerbrugge CM, Bloemen RJ, Koedam JA & Van Neck JW 2000 Human insulin-like growth factor (IGF) binding protein-1 inhibits IGF-I-stimulated body growth but stimulates growth of the kidney in snell dwarf mice. Endocrinology 141 1493-1499. (doi:10.1210/endo.141.4.7418)
46. Wallander M, Norhammar A, Malmberg K, Ohrvik J, Ryden L & Brismar K 2007 IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 30 2343-2348. (doi:10.2337/dc07-0825)
47. Wang J, Razuvaev A, Folkersen L, Hedin E, Roy J, Brismar K & Hedin U 2012 The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis 220 102-109. (doi:10.1016/j.atherosclerosis.2011.10.032)
48. Yamano T, Niijima A, Iimori S, Tsuruoka N, Kiso Y & Nagai K 2001 Effect of L-carnosine on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats. Neuroscience Letters 313 78-82. (doi:10.1016/S0304-3940(01)02231-5)
49. Yapislar H & Aydogan S 2012 Effect of carnosine on erythrocyte deformability in diabetic rats. Archives of Physiology and Biochemistry 118 265-272. (doi:10.3109/13813455.2012.714790)
50. Zachrisson I, Dahlquist G, Wallensteen M & Brismar K 2000 Insulin-like growth factor binding protein-1 as glucose regulator in adolescent boys with type 1 diabetes. Acta Paediatrica 89 1044-1049. (doi:10.1111/j.1651-2227.2000.tb03348.x)